<div id="readability-page-1"><p>Hansa Biopharma ((SE:HNSA)) has held its Q4 earnings call. Read on for the main highlights of the call.</p><h3>Valentine's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Hansa Biopharma’s latest earnings call struck a cautiously upbeat tone, blending strong revenue growth and a reinforced balance sheet with frank discussion of clinical setbacks and commercial headwinds. Management stressed confidence in its 2026 execution plan, but investors were reminded that regulatory decisions and launch performance remain decisive for value creation.</p> <h2>Strong topline growth underpins investment case</h2> <p>Q4 total revenue jumped to SEK 76.0M, up 135% year-on-year, driven by Idefirix product sales of SEK 61.1M, up 139%. For 2025, total revenue reached SEK 222.3M, with product sales of SEK 204.7M, which the company described as roughly 46% growth versus the prior year, reinforcing momentum in its core franchise.</p> <h2>Equity raise extends cash runway into 2027</h2> <p>Hansa completed a SEK 671.5M direct share issue in Q4, leaving cash and equivalents at SEK 701M at year-end 2025. Management said this capital should fund operations into 2027, giving the company time to pursue regulatory approvals, ramp commercialization, and reach key clinical milestones without near-term financing pressure.</p> <h2>BLA filing sets stage for U.S. launch</h2> <p>The company submitted a BLA for Imlifidase to the FDA in December 2025 and now awaits acceptance and a PDUFA date. At the same time, Hansa is building U.S. launch infrastructure, including NTAP applications, expanding market access and field teams, senior commercial hires, and detailed targeting across about 200 transplant centers.</p> <h2>Cost discipline narrows operating loss</h2> <p>R&amp;D spending fell to SEK 304.7M in 2025, down about 19% from 2024, with Q4 R&amp;D at SEK 74.4M, down 26%. Combined with revenue growth, this helped shrink the full-year operating loss to SEK 521M, an 18% improvement, and Q4 operating loss to roughly SEK 125M, down 28% year-on-year.</p> <h2>Pipeline advances toward key 2026 readouts</h2> <p>The ConfIdeS trial in the U.S. delivered a positive readout and new data, while five-year Idefirix outcomes were published in Transplant International. Looking ahead, Hansa expects a European Phase III PAES readout and more real-world evidence in 2026, and is preparing HNSA-5487 for a late-stage GBS trial initiation that same year.</p> <h2>European access footprint broadens</h2> <p>Reimbursement for Idefirix is now in place across 24 European countries, expanding the treatment’s reach in desensitization. Recent wins include Slovakia gaining reimbursement, temporary funding secured in Catalonia, and special access via the French ANSM for lung transplants, highlighting the influence of key opinion leaders in driving use.</p> <h2>Operations reshaped for global competition</h2> <p>Management highlighted 2025 as a transformational year, citing a stronger senior leadership team, renegotiated debt, and two equity raises. The European commercial organization has been reorganized, with Max Sakajja appointed to lead Europe and international markets, aiming to sharpen execution as Hansa readies for broader global competition.</p> <h2>Anti-GBM setback narrows near-term indications</h2> <p>The Phase III anti-GBM trial failed to meet its primary eGFR endpoint at six months or key secondary measures like kidney function. There was also no difference in end-stage kidney disease or death at six months, and Hansa will not pursue further anti-GBM trials, instead focusing on subgroup analyses and other pipeline priorities.</p> <h2>European launch remains uneven and visibility limited</h2> <p>Management described the European rollout as unusual, constrained early on by limited clinical experience and a major ongoing Phase III trial. They guided to relatively weak Q1 2026 revenues in Europe as reorganization and change management continue, with expectations that performance should strengthen into the second half of 2026.</p> <h2>Germany disruption weighs on near-term growth</h2> <p>A key headwind is Germany’s pause in the Eurotransplant Priority Program for highly sensitized patients, a significant market for Idefirix. Resolution depends on governmental decisions with no quick workaround, and updated clinical guidance driven by experts may not provide clarity until the first half of 2026, prolonging uncertainty.</p> <h2>Cash burn and losses still material</h2> <p>Despite progress, Hansa remains loss-making, with a full-year operating loss of SEK 521M and reported cash used in operations of SEK 149M. Management reiterated that advancing toward profitability hinges on regulatory approvals and successful commercialization of Imlifidase, particularly in the U.S. and improved European performance.</p> <h2>U.S. reimbursement remains a swing factor</h2> <p>The company views the U.S. reimbursement framework via DRGs, outlier payments, and a potential NTAP as structurally sound but inherently variable. Outlier and center-level payment outcomes are not guaranteed, NTAP is not assured, and pricing work continues against a European list-price reference, while MFN policy risk is monitored but not seen as near-term.</p> <h2>Partnership optionality clouded by timing</h2> <p>The collaboration with Sarepta remains in place, but the timeline for next steps and clearer communication is uncertain as Sarepta focuses on its own regulatory agenda. That leaves one of Hansa’s external growth levers harder for investors to model in the near term, even as core transplant and GBS programs move ahead.</p> <h2>Guidance: 2026 as an inflection year</h2> <p>Management framed 2026 as a potential inflection year, expecting imminent FDA acceptance of the BLA and targeting full launch readiness by the PDUFA decision. They anticipate a weak Q1 but stronger second half in Europe as the new structure beds in, while also aiming to initiate a late-stage HNSA-5487 GBS trial before year-end.</p> <p>Hansa Biopharma’s earnings call painted a picture of a company exiting a transitional year with stronger finances, better cost control, and a clearer regulatory roadmap. Investors now face a classic biotech setup: meaningful upside tied to U.S. approval and commercialization, offset by operational, reimbursement, and clinical execution risks that will define returns into 2027.</p></div>

IBBQ

<p>Hansa Biopharma's Q4 earnings call highlighted strong revenue growth, with total revenue up 135% year-on-year to SEK 76.0M, driven by Idefirix sales. The company raised SEK 671.5M to extend its cash runway into 2027, supporting regulatory approvals and commercialization efforts. Despite a failed Phase III anti-GBM trial, Hansa is preparing for a U.S. launch of Imlifidase and expanding its European market access. However, challenges remain, including a pause in Germany's Eurotransplant program and ongoing cash burn, with a full-year operating loss of SEK 521M.</p>

Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot